---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004942"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:32:29.603028+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Fulcrum expects ~$240M cash at year-end 2024 (preliminary)

## Summary
- Expects approximately $240M in cash, equivalents and marketable securities as of Dec 31, 2024 (preliminary, unaudited).
- Full Q4 and FY2024 financial results not yet finalized; audit ongoing.
- Updated corporate presentation published on January 13, 2025 on company website.

## SEC filing metadata
- accession: 0001193125-25-004942
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000119312525004942/0001193125-25-004942-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000119312525004942/d714885d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004942
- JSON: https://secwatch.observer/filing/0001193125-25-004942.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004942.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.